Literature DB >> 12752031

A longitudinal analysis of the impact of social and clinical characteristics on the costs of schizophrenia treatment.

R Kilian1, H Matschinger, T Becker, M C Angermeyer.   

Abstract

OBJECTIVE: The aim of the study was the longitudinal analysis of the influence of social and clinical factors on the mid-term costs of schizophrenia treatment.
METHOD: Treatment costs as well as clinical and social characteristics of 307 patients with the ICD-10 diagnosis of schizophrenia were assessed at five follow-ups over 2.5 years. Between and within effects of clinical and social characteristics on treatment costs were estimated by error component regression models.
RESULTS: Effects caused by differences between individuals were found for age, partnership, in-patient history, objective and subjective role functioning, life-events and psychotic relapse. Effects of idiosyncratic transitory changes of social and clinical characteristics were found for symptoms, psychotic relapse, and for social role-functioning.
CONCLUSION: Treatment costs can be reduced to a limited extent not only by the prevention of psychotic symptoms and relapse but also by the improvement of role-functioning capacities.

Entities:  

Mesh:

Year:  2003        PMID: 12752031     DOI: 10.1034/j.1600-0447.2003.00072.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  9 in total

Review 1.  Mental health care in Germany: current state and trends.

Authors:  Hans Joachim Salize; Wulf Rössler; Thomas Becker
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-03       Impact factor: 5.270

Review 2.  The Cost of Relapse in Schizophrenia.

Authors:  Mark Pennington; Paul McCrone
Journal:  Pharmacoeconomics       Date:  2017-09       Impact factor: 4.981

3.  Overview and emerging trends.

Authors:  Sandeep Grover; Ajit Avasthi; Subho Chakrabarti; Paramanand Kulhara
Journal:  Indian J Psychiatry       Date:  2005-10       Impact factor: 1.759

4.  Effectiveness and efficiency of assertive outreach for Schizophrenia in Germany: study protocol on a pragmatic quasi-experimental controlled trial.

Authors:  Anke Bramesfeld; Jörn Moock; Kirsten Kopke; Dorothea Büchtemann; Denise Kästner; Jeanett Radisch; Wulf Rössler
Journal:  BMC Psychiatry       Date:  2013-02-15       Impact factor: 3.630

5.  Duration of bed occupancy as calculated at a random chosen day in an acute care ward. Implications for the use of scarce resources in psychiatric care.

Authors:  John E Berg; Asbjørn Restan
Journal:  Ann Gen Psychiatry       Date:  2005-05-27       Impact factor: 3.455

6.  Empirically driven definitions of "good," "moderate," and "poor" levels of functioning in the treatment of schizophrenia.

Authors:  Haya Ascher-Svanum; Diego Novick; Josep Maria Haro; Jaume Aguado; Zhanglin Cui
Journal:  Qual Life Res       Date:  2012-12-14       Impact factor: 4.147

7.  Evaluation of a Family-Based Intervention Program for Children of Mentally Ill Parents: Study Protocol for a Randomized Controlled Multicenter Trial.

Authors:  Silke Wiegand-Grefe; Bonnie Filter; Mareike Busmann; Reinhold Kilian; Klaus-Thomas Kronmüller; Martin Lambert; Christine Norra; Kai von Klitzing; Kurt Albermann; Sibylle Maria Winter; Anne Daubmann; Karl Wegscheider; Angela Plass-Christl
Journal:  Front Psychiatry       Date:  2021-01-20       Impact factor: 4.157

8.  Needs-oriented discharge planning and monitoring for high utilisers of psychiatric services (NODPAM): design and methods.

Authors:  Bernd Puschner; Sabine Steffen; Wolfgang Gaebel; Harald Freyberger; Helmfried E Klein; Tilman Steinert; Rainer Muche; Thomas Becker
Journal:  BMC Health Serv Res       Date:  2008-07-21       Impact factor: 2.655

9.  A Method to Compare the Delivery of Psychiatric Care for People with Treatment-Resistant Schizophrenia.

Authors:  Anna Alonso-Solís; Susana Ochoa; Eva Grasa; Katya Rubinstein; Asaf Caspi; Kinga Farkas; Zsolt Unoka; Judith Usall; Elena Huerta-Ramos; Matti Isohanni; Jussi Seppälä; Elisenda Reixach; Jesús Berdún; Iluminada Corripio; M-Resist Group
Journal:  Int J Environ Res Public Health       Date:  2020-10-16       Impact factor: 3.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.